Skip to main content
Fig. 3 | Health Economics Review

Fig. 3

From: Cost-effectiveness analysis of combination therapies involving novel agents for first/second-relapse patients with multiple myeloma: a Markov model approach with calibration techniques

Fig. 3

Modelled costs and effectiveness for combination therapies. Ai: cumulative costs in bortezomib group, Aii: costs associated with different states in the bortezomib group, Aiii: cumulative QALYs in bortezomib group, Aiv: costs associated with different states in the bortezomib group; Bi: cumulative costs in lenalidomide group, Bii: costs associated with different states in the lenalidomide group, Biii: cumulative QALYs in lenalidomide group, Biv: costs associated with different states in the lenalidomide group; Ci: cumulative costs in carfilzomib group, Cii: costs associated with different states in the carfilzomib group, Ciii: cumulative QALYs in carfilzomib group, Civ: costs associated with different states in the carfilzomib group

Back to article page

Health Economics Review

ISSN: 2191-1991

Contact us